A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- CRC
- KRAS Gene Mutation
- NSCLC
- Solid Tumors
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03965845
- Collaborators
- Not Provided
- Investigators
- Study Director: Sam Whiting, MD, PhD Calithera Biosciences, Inc